Skip to main content
. 2019 Apr 17;37(16):1391–1402. doi: 10.1200/JCO.18.01460

FIG 4.

FIG 4.

Cumulative rates of all-grade and grade 3 or greater (A) diarrhea/colitis and (B) abnormal LFTs in the IDELA/R-to-IDELA group. Inset tables provide incidence rates by 12-week intervals. IDELA, idelalisib; LFT, liver function tests; R, rituximab.